tbuckley/cabot-search huggingface dataset:
The American Medical Association Physician's Recognition Award
Journal: JAMA (1969)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Error in Figure 2
Journal: JAMA Network Open (2019)

Jieming Chen, PhD; Sanchita Bhattacharya, MS; Marina Sirota, PhD; Sunisa Laiudompitak, MS; Henry Schaefer, PhD; Elizabeth Thomson, MBA; Jeff Wiser, MS; Minnie M. Sarwal, MD, PhD; Atul J. Butte, MD, PhD
STATE REGULATION OF MEDICAL COLLEGES AND MEDICAL EDUCATION.
Journal: JAMA (1902)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
<i>Erratum:</i> Vol. 60, No. RR-1
Journal: MMWR Morbidity and Mortality Weekly Report (2017)

In the Recommendations and Reports "Antiviral Agents for the Treatment and Chemoprophylaxis of Influenza" (January 21, 2011, Vol. 60, No. RR-1, https://www.cdc.gov/mmwr/pdf/rr/rr6001.pdf), on page 8, in the first column, in the second paragraph, in the second sentence, the term "pneumonia" was used rather than "lower respiratory tract complications leading to antibiotic use." The corrected sentence should read, "In a study that combined data from 10 clinical trials, the risk for lower respiratory tract complications leading to antibiotic use among those participants with laboratory-confirmed influenza receiving oseltamivir treatment was approximately 50% lower than among those persons receiving a placebo and 34% lower among patients at risk for complications (p<0.05 for both comparisons) (22)."
Monitoring Warfarin Therapy in Patients with Lupus Anticoagulants
Authors: Stephan Moll
Journal: Annals of Internal Medicine (1998)

Letters15 March 1998Monitoring Warfarin Therapy in Patients with Lupus AnticoagulantsStephan Moll, MD and Thomas L. Ortel, MD, PhDStephan Moll, MDMedizinische Fakultat Charite der Humboldt-Universitat zu Berlin; 13122 Berlin, GermanyDuke University Medical Center; Durham, NC 27710Search for more papers by this author and Thomas L. Ortel, MD, PhDMedizinische Fakultat Charite der Humboldt-Universitat zu Berlin; 13122 Berlin, GermanyDuke University Medical Center; Durham, NC 27710Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-128-6-199803150-00018 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail IN RESPONSE:Dr. Manoharan asks about the Thrombotest, which was described by Owren in 1959 as an alternative to Quick's thromboplastin time (prothrombin time) for monitoring oral anticoagulant therapy [1]. The Thrombotest was designed to be sensitive to decreases in levels of all four vitamin K-dependent procoagulant factors (factors II, VII, IX, and X), whereas Quick's test was sensitive to decreases in levels of factors II, VII, and X only. The original Thrombotest reagent consisted of an active cephalin and a low-activity thromboplastin to activate both intrinsic and extrinsic pathways. In addition, the sample was diluted into adsorbed bovine plasma ...References1. Owren PA. Thrombotest. A new method for controlling anticoagulant therapy. Lancet. 1959; 2:754-8. Google Scholar2. Sise HS, Lavelle SM, Adamis D, Becker R. Relation of hemorrhage and thrombosis to prothrombin during treatment with coumarin-type anticoagulants. N Engl J Med. 1958; 259:266-71. Google Scholar3. Zivelin A, Rao LV, Rapaport SI. Mechanism of the anticoagulant effect of warfarin as evaluated in rabbits by selective depression of individual procoagulant vitamin K-dependent clotting factors. J Clin Invest. 1993; 92:2131-40. Google Scholar4. Le DT, Weibert RT, Sevilla BK, Donnelly KJ, Rapaport SI. The international normalized ratio (INR) for monitoring warfarin therapy: reliability and relation to other monitoring methods. Ann Intern Med. 1994; 120:552-8. Google Scholar Author, Article, and Disclosure InformationAffiliations: Medizinische Fakultat Charite der Humboldt-Universitat zu Berlin; 13122 Berlin, GermanyDuke University Medical Center; Durham, NC 27710 PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics 15 March 1998Volume 128, Issue 6Page: 504-505KeywordsAnimal modelsAnticoagulant therapyAnticoagulantsBlood plasmaFibrinogenPartial thromboplastin timePhospholipidsProthrombin time Issue Published: 15 March 1998 Copyright & PermissionsCopyright © 1998 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...
QuickStats: Age-Adjusted Death Rates* for Lung Cancer,† by Urbanization of County of Residence§ — National Vital Statistics System, United States, 2006 and 2016
Journal: MMWR Morbidity and Mortality Weekly Report (2018)

Large central Large fringe (Suburban) Medium Small Micropolitan Noncore 2006 2016 Deaths per 100,000 population Metropolitan areas Nonmetropolitan areas * Deaths per 100,000 population age-adjusted to the 2000 U.S. standard population with 95% confidence intervals.† Lung cancer deaths were identified with the International Classification of Diseases, Tenth Revision underlying cause of death code C34.§ Counties were classified into six urbanization levels based on a classification scheme developed by the National Center for Health Statistics that considers metropolitan/nonmetropolitan status, population, and other factors.From 2006 to 2016, the age-adjusted death rate for lung cancer decreased in each of the six urbanization levels, with the largest decrease (29%) in large central metropolitan counties and the smallest decrease (16%) in noncore counties.In both years, the rate of lung cancer death was higher in nonmetropolitan areas than in metropolitan areas.In 2016, the lung cancer death rate in noncore counties was 48.6 per 100,000 compared with 33.0 in large central metropolitan counties.
UNITED KINGDOM
Journal: JAMA (1963)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Vancomycin
Authors: Anthony L. Esposito
Journal: JAMA (1977)

WITH the introduction of methicillin sodium into clinical practice in 1960, the antibiotic vancomycin hydrochloride was relegated to the back shelves of the hospital pharmacy or deleted from the formulary. This appeared to be a natural evolutionary process: a toxic medicine replaced by one with less potential for serious untoward events. Vancomycin was known to be a difficult antibiotic for the patient to tolerate, since the administration of this compound could precipitate phlebitis, shaking chills, fever, and generalized skin eruptions. More importantly, however, vancomycin had produced irreparable harm to some patients, including deafness and renal failure.<sup>1</sup>We report why vancomycin should not be considered merely a drug of historic interest and why it remains an essential component of the physician's therapeutic arsenal. Three factors appear to contribute to the need for a second look at vancomycin: improvements in the manufacturing process have produced a preparation that has resulted in a
JAMA Pediatrics
Authors: Phil Fontanarosa, Annette Flanagin, Paula Glitman, Brenda Gregoline, Tracy Frey, Shannon Sparenga, Miriam Cintron, Paul Ruich, Diane Cannon, Vickey Golden, Connie Manno, Laura Copyreaders, Catherine Adamcyzk, Jan Alden, Mary Clavey, Cheryl Coerver-Connolly, Gillian Davidow, Laura Dickens, Juliann King, Donna Tarsney, Caroline Thordsen, Wanda Assistant, Larry Bryant, Monica Mungle, Elaine Williams, Lenette Gardner-Gullens, Fanny Brown, Paul Frank, Rachell Lozano, Michaela Mark, Kathryn Muskovich, J Neff, Kate Pezalla, Gale Saulsberry, Michael Berkwits, Michelle Kurzynski, Eric Butkus, Christopher Hastings, Craig Mccaffrey, Reuben Rios, Ronna Henry, Staff Bird, Alison Burke, Cassio Lynm, David Song, Deputy Livingston, Thomas Cole, Marla Hall, Deanna Willis, Yolanda Davis, Joseph Thornton, Jann Ingmire, Deanna Bellandi, Jim Periodical, Thomas Staff, Monica Smith, Jeffery Bonistalli Manager, Kathy Staff, Mirna Monal, Tim Melroy, Thalia Moss, Tem Harrier, Susan Henning, Mark Thornbury, Tricia Castellano, Saskia Bolore, Gretchen Linder, Brian Mccartney, Rebecca Haas, Christine Hearne, Irma Lara, Audra Lawlor, Scott Marketing, Matt Herron, Elizabeth Solaro, Geoffrey Flick Managers, Rick Bell, Paul Gee, Michael Mcgraw, Sara Nagy, Stacy Staff, Millette Jackson-Bates, Karen Adams-Taylor, Karl Elvin, Sue Sherrill, Brian Shields Managers, David Antos, Chris Borden, Debbie Camp, Lydia Cruz, Diane Darnell, Colleen Kelly, Chris Meyer, Emily Mitchell, Jaye Mize, Sean O'donnell, Sean Ohlson, Phil O'leary, Ryan Patella, Susan Price, Denise Steinhauser, Production Services, Kim Boler, Rhonda Brown, Timothy Burke, Susan Chiara, Daniel Degroot, Jordynn Farrar, Euwanaha Joiner-Smith, Cindy Rendlen, Ellen Yoshihara, Circulation Services, Julie Burton, Dexter Golden, Erin Hinchcliff, Noemi Rivera, Geneine Van, Someren Composition, New Media, Gail Barrett, Regina Brownlee, Brenda Chandler-Grayer, Scott Curl, Amy Evers, Teri Hutchison, Mary Kuranda, Joshua Lampinen, Fred Marshall, Patricia Panek, La Son, Diggs Sledge, George Thomson Graphics, Joe Amft, Maria Duda, Fred Furtner, Carolyn Hall, Maria Kowalkowski, Proofreading Carol, Joy Farrell, Daniel James, Judith Literskis, Teresa Omiotek, James Madara, Bernard Hengesbaugh, Dimitri Christakis, Washington Joffe, Ron Keren, Suzanne Shuey, Benjamin French, Peter Cummings, Samir Shah, Howard Bauchner, Frederick Rivara, Matthew Davis, Ann Arbor, Cherrie Boyer, San Francisco, Robert Bradley, Maria Britto, John Campo, Aaron Carroll, Indiana Frank, Joseph Chaloupka, Mitchell Cohen, Chris Feudtner, Kathleen Janz, Iowa City, Terry Klassen, Joyce Lee, Michigan Michelle, Huckaby Lewis, Maryland Saiman, New York, York Samir, Martha Sola-Visner, Jean-Claude Carel, Shabir Madhi, Ben Marais, Frank Oberklaid, Susan Sawyer, Joan-Carles Surís
Journal: JAMA Pediatrics (2013)
Commercial Weight Loss Programs
Authors: Adam Gilden Tsai
Journal: Annals of Internal Medicine (2005)

Letters21 June 2005Commercial Weight Loss ProgramsAdam Gilden Tsai, MD and Thomas A. Wadden, PhDAdam Gilden Tsai, MDFrom the University of Pennsylvania, Philadelphia, PA 19104.Search for more papers by this author and Thomas A. Wadden, PhDFrom the University of Pennsylvania, Philadelphia, PA 19104.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-142-12_Part_1-200506210-00018 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail IN RESPONSE:Dr. Gotthelf cites our call for naturalistic studies to determine the effectiveness of weight loss programs and states that she offered such data, which we declined. We outlined very specific criteria for original research to be included in our review, one of which was that the data had to be published in a journal. We applaud Health Management Resources for collecting further data from observational studies and encourage the company to submit these findings for peer review.Dr. Gotthelf states that we concluded that Weight Watchers was the most successful program. We did not state this, but rather ...References1. Anderson JW, Hamilton CC, Crown-Weber E, Riddlemoser M, Gustafson NJ. Safety and effectiveness of a multidisciplinary very-low-calorie diet program for selected obese individuals. J Am Diet Assoc. 1991;91:1582-4. [PMID: 1960353] CrossrefMedlineGoogle Scholar2. Clinical Guidelines on the Identification, Evaluation, and Treatment of Overweight and Obesity in Adults—The Evidence Report. National Institutes of Health. Obes Res. 1998;6 Suppl 2 51S-209S. [PMID: 9813653] MedlineGoogle Scholar3. Partnership for Healthy Weight Management. Voluntary Guidelines for Providers of Weight Loss Products or Services. Accessed at www.consumer.gov/weightloss in October 2003. Google Scholar Author, Article, and Disclosure InformationAffiliations: From the University of Pennsylvania, Philadelphia, PA 19104.Disclosures: Consultancies and grants received: T.A. Wadden (Novartis Nutrition, manufacturer of OPTIFAST). PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetailsSee AlsoSystematic Review: An Evaluation of Major Commercial Weight Loss Programs in the United States Adam Gilden Tsai and Thomas A. Wadden Commercial Weight Loss Programs Linda Gotthelf Commercial Weight Loss Programs Linda Gotthelf Metrics 21 June 2005Volume 142, Issue 12_Part_1Page: 1024-1025KeywordsConflicts of interestDietFoodHealth information technologyNutritionObservational studiesPeer reviewWeight loss ePublished: 21 June 2005 Issue Published: 21 June 2005 CopyrightCopyright © 2005 by American College of Physicians. All Rights Reserved.PDF DownloadLoading ...
Theroretical Principles of Methods of Analytical Chemistry Based on Chemical Reactions.
Journal: JAMA (1910)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Accredited Visiting Faculty Program on Colorectal Cancer
Journal: JNCI Journal of the National Cancer Institute (1982)

Journal Article Accredited Visiting Faculty Program on Colorectal Cancer Get access JNCI: Journal of the National Cancer Institute, Volume 69, Issue 3, September 1982, Page 745, https://doi.org/10.1093/jnci/69.3.745-c Published: 01 September 1982
The Nonrheumatic Uses of Latex Fixation Tests
Journal: JAMA (1963)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Negative Ions of Polyatomic Molecules
Authors: L. G. Christophorou
Journal: Environmental Health Perspectives (1980)

In this paper general concepts relating to, and recent advances in, the study of negative ions of polyatomic molecules area discussed with emphasis on halocarbons. The topics dealt with in the paper are as follows: basic electron attachment processes, modes of electron capture by molecules, short-lived transient negative ions, dissociative electron attachment to ground-state molecules and to "hot" molecules (effects of temperature on electron attachment), parent negative ions, effect of density, nature, and state of the medium on electron attachment, electron attachment to electronically excited molecules, the binding of attached electrons to molecules ("electron affinity"), and the basic and the applied significance of negative-ion studies.
Endocarditis in a Woman With Pulmonary Histiocytosis—Correction
Authors: L La Grenade, D J Graham, P Nourjah
Journal: JAMA (2001)

To the Editor: Although passive surveillance systems for adverse drug event reporting are often used to detect rare, serious adverse reactions for marketed drugs, they are limited by underreporting.The extent of underreporting is unknown and may be influenced by the severity of the event, the specialty of the reporter, how long the drug has been on the market, whether the event is labeled, and whether the drug is prescription or nonprescription. 1 We attempted to assess the degree of underreporting of hemorrhagic stroke associated with phenylpropanolamine, a nonprescription drug.Methods.We compared the number of cases of hemorrhagic stroke associated with phenylpropanolamine detected in the Hemorrhagic Stroke Project 2 with those reported during the same period to the Adverse Event Reporting System of the US Food and Drug Administration (FDA).The Hemorrhagic Stroke Project study was conducted between December 1994 and July 1999 in Connecticut, Massachusetts, Ohio, Kentucky, Rhode Island, and Texas.In an effort to recruit all research subjects who were 18 to 49 years of age and in the areas under study and who had had a hemorrhagic stroke, the Hemorrhagic Stroke Project developed an active surveillance program for hemorrhagic stroke in selected hospitals of the participating states.Results.In the 5-year period under study, the Hemorrhagic Stroke Project enrolled 702 participants who had had hemorrhagic stroke and were in the target age group, 27 of whom had been exposed to phenylpropanolamine.During the same period, no states or hospitals in the study area reported cases to the Adverse Event Reporting System.The reporting rate was thus 0% (95% confidence interval, 0%-10.5%).Comment.This very low rate of passive reporting is consistent with previous estimates.Scott et al 3 estimated that less than 1% of suspected serious adverse reactions were reported to the FDA in the 1980s.Rogers et al 1 found that physicians reported only 8% to 13% of serious or life-threatening adverse reactions.We were unable to identify any prior studies of underreporting of a serious adverse reaction caused by a nonprescription drug in the United States.
Social Work Year Book, 1929.
Journal: JAMA (1931)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal